Secondary objectives include changes in HOMA-β (islet β-cell function), C-peptide index, the insulin response to glucose calculated from the oral glucose tolerance test (OGTT) and insulin releasing test (Ins), frequency of the regular menstrual cycle and ovulation, circulating sex steroids, lipid profile, health-related quality of life and symptoms of anxiety and depression, side effects, and credibility. This evidence concerns the gene INS and depressive disorder.